Dr Golo Ahlenstiel

Associate Professor
Medicine, Westmead Clinical School

Telephone +61 2 9845 7986
Fax 61 2 9845 5118

Map

Biographical details

After completing his doctoral degree in immunogenetics at the University of Bonn, Germany, Golo Ahlenstiel received research fellowship awards from the National Institutes of Health (NIH, USA) and from the German Research Foundation (DFG, Germany) to work in the Rehermann laboratory at the NIH on the immunopathogenesis of viral hepatitis, in particular the role of innate immunity in HCV infection. Since moving to Australia, Golo Ahlenstiel has continued his research on the role of IL28B in HCV infection at the Storr Liver Unit, Westmead. Golo Ahlenstiel is currently also a Staff Specialist in Gastroenterology and Hepatology at Westmead Hospital.

Research interests

Dr Ahlenstiel undertakes basic science and translational research in chronic liver disease. His research investigates the role of the host immune system in pathogenesis and therapy of hepatitis C virus infection using state of the art GWAS, multicolour flow cytometry and genomics. The overall aim of Dr. Ahlenstiel's research is to better understand the mechanisms that lead to chronicity, fibrogenesis and treatment response of viral hepatitis in order to identify new targets for drug development and biomarkers predicting disease progression.

Teaching and supervision

Dr Ahlenstiel takes active role in the clinical teaching of medical students of the University of Sydney, as well as JMO and BPT teaching.

Associations

AASLD

EASL

GESA

DGIM

DGVS

International links

Germany

(Universitaetsklinikum Bonn, Bonn, Germany) Immunogenetics in HCV infection with Prof. Ulrich Spengler and Prof. Jacob Nattermann

Germany

(University Hospital Leipzig, Leipzig, Germany) Immunogenetics in HCV with Prof. Thomas Berg

Selected grants

2014

  • The role of interferon lambda 3 in HCU related liver disease; Ahlenstiel G; DVC Research/Bridging Support Grant.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Ahlenstiel, G., Rehermann, B. (2007). Hepatic NK, NKT and T Cells. In M Eric Gershwin, John M. Vierling, Michael P. Manns (Eds.), Liver Immunology - Principles and Practice, (pp. 71-82). United States of America: Humana Press, Inc.

Journals

  • Beard, M., Ffrench, R., Gowans, E., Helbig, K., Eyre, N., Douglas, M., Grebely, J., Ahlenstiel, G., Locarnini, S., George, J., et al (2014). A Summary of the 20(th) International Symposium on Hepatitis C Virus and Related Viruses. Gastroenterology, 147(1), e1-e4. [More Information]
  • Ahlenstiel, G., Hourigan, L., Brown, G., Zanati, S., Williams, S., Singh, R., Moss, A., Sonson, R., Bourke, M. (2014). Actual endoscopic versus predicted surgical mortality for treatment of advanced mucosal neoplasia of the colon. Gastrointestinal Endoscopy, 80(4), 668-676. [More Information]
  • Rotman, Y., Noureddin, M., Feld, J., Guedj, J., Witthaus, M., Han, H., Park, Y., Park, S., Heller, T., Ghany, M., Ahlenstiel, G., et al (2014). Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut (English Edition): an international journal of gastroenterology and hepatology, 63(1), 161-169. [More Information]
  • O'Connor, K., Parnell, G., Patrick, E., Ahlenstiel, G., Suppiah, V., van der Poorten, D., Read, S., Leung, R., Douglas, M., Yang, J., Stewart, G., Liddle, C., George, J., Booth, D. (2014). Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent. Genes and Immunity, 15(2), 88-94. [More Information]
  • Eslam, M., Leung, R., Romero-Gomez, M., Mangia, A., Irving, W., Sheridan, D., Spengler, U., Mollison, L., Cheng, W., Bugianesi, E., Douglas, M., Booth, D., George, J., Ahlenstiel, G., et al (2014). IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. Journal of Hepatology, 61(2), 235-241. [More Information]
  • Suppiah, V., Armstrong, N., O'Connor, K., Berg, T., Weltman, M., Abate, M., Spengler, U., Bassendine, M., Dore, G., Irving, W., Stewart, G., George, J., Booth, D., Ahlenstiel, G., et al (2013). CCR5-Delta32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection. Genes and Immunity, 14(5), 286-290. [More Information]
  • Ahlenstiel, G., Sonson, R., Bourke, M. (2013). Diagnosis and treatment of radiation proctitis. Video Journal and Encyclopedia of GI Endoscopy, 1(2), 316-317. [More Information]
  • Eslam, M., Booth, D., George, J., Ahlenstiel, G. (2013). Interaction of IFNL3 with insulin resistance, steatosis and lipid metabolism in chronic hepatitis C virus infection. World Journal of Gastroenterology, 19(41), 7055-7061. [More Information]
  • O'Day, R., Gillies, M., Ahlenstiel, G. (2013). Ophthalmologic complications of antiviral therapy in hepatitis C treatment. World Journal of Gastroenterology, 19(45), 8227-8237. [More Information]
  • Ahlenstiel, G. (2013). The Natural Killer Cell Response to HCV Infection. Immune Network, 13(5), 168-176. [More Information]
  • Edlich, B., Ahlenstiel, G., Azpiroz, A., Stoltzfus, J., Noureddin, M., Serti, E., Feld, J., Liang, T., Rotman, Y., Rehermann, B. (2012). Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients. Hepatology (Baltimore Md.), 55(1), 39-48. [More Information]
  • Booth, D., Ahlenstiel, G., George, J. (2012). Pharmacogenomics of hepatitis C infections: personalizing therapy. Genome Medicine, 4(12), 1-10. [More Information]
  • Ahlenstiel, G., Booth, D., George, J. (2012). Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms? Antiviral Therapy, 17(6 Pt B), 1163-1170. [More Information]
  • Ahlenstiel, G., Booth, D., George, J. (2011). Clinical significance of IL28B gene variation in hepatitis C virus infection. Hot Topics in viral Hepatitis, (20), 17-24. [More Information]
  • Ahlenstiel, G., Edlich, B., Hogdal, L., Rotman, Y., Noureddin, M., Feld, J., Holz, L., Titerence, R., Liang, T., Rehermann, B. (2011). Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology, 141(4), 1231-1239. [More Information]
  • Smith, K., Suppiah, V., O'Connor, K., Berg, T., Weltman, M., Abate, M., Spengler, U., Bassendine, M., Matthews, G., Irving, W., Ahlenstiel, G., Stewart, G., George, J., Booth, D., et al (2011). Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Medicine, 3(8), 57-1-57-13. [More Information]
  • Suppiah, V., Gaudieri, S., Armstrong, N., O'Connor, K., Berg, T., Weltman, M., Abate, M., Spengler, U., Bassendine, M., Dore, G., Ahlenstiel, G., Stewart, G., George, J., Booth, D., et al (2011). IL28B, HLA-C, and KIR Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort: A Cross-Sectional Study. PLoS Medicine, 8(9), e1001092-1-e1001092-8. [More Information]
  • Feld, J., Modi, A., El-Diwany, R., Rotman, Y., Thomas, E., Ahlenstiel, G., Titerence, R., Koh, C., Cherepanov, V., Heller, T., et al (2011). S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders. Gastroenterology, 140(3), 830-839. [More Information]
  • Ahlenstiel, G., Booth, D., George, J. (2010). IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice. Journal of Gastroenterology and Hepatology, 45(9), 903-910. [More Information]
  • Ahlenstiel, G., Titerence, R., Koh, C., Edlich, B., Feld, J., Rotman, Y., Ghany, M., Hoofnagle, J., Liang, J., Heller, T., et al (2010). Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology, 138, 325-335. [More Information]
  • Vogel, M., Ahlenstiel, G., Hintsche, B., Fenske, S., Trein, A., Lutz, T., Schurmann, D., Stephan, C., Khaykin, P., Bickel, M., et al (2010). The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive Individuals. European Journal of Medical Research, 15(3), 102-111. [More Information]
  • Ahlenstiel, G., Woitas, R., Iwan, A., Nattermann, J., Feldmann, G., Rockstroh, J., Oldenburg, J., Kupfer, B., Sauerbruch, T., Spengler, U. (2009). Effects of the CCR5-Delta32 mutation on hepatitis C virus-specific immune responses in patients with haemophilia. Immunological Investigations, 38(3-4), 284-296. [More Information]
  • Mas Marques, A., Mueller, T., Welke, J., Taube, S., Sarrazin, C., Wiese, M., Halangk, J., Witt, H., Ahlenstiel, G., Spengler, U., et al (2009). Low-density lipoprotein receptor variants are associated with spontaneous and treatment-induced recovery from hepatitis C virus infection. Infection, Genetics and Evolution, 201(5), 27-36. [More Information]
  • Yoon, J., Shjiina, M., Ahlenstiel, G., Rehermann, B. (2009). Natural killer cell function is intact after direct exposure to infectious hepatitis C virions. Hepatology, 49(1), 12-21. [More Information]
  • De Zorzi, M., Caggiari, L., Ahlenstiel, G., Rehermann, B., De Re, V. (2008). Description of two new major histocompatibility complex (MHC) class II DRB1 [Pan troglodytes (Patr)-DRB1] alleles. Tissue Antigens: immune response genetics, 71(5), 490. [More Information]
  • Ahlenstiel, G., Martin, M., Gao, X., Carrington, M., Rehermann, B. (2008). Distinct KIR/HLA compound genotypes affect the kinetics of human antiviral natural killer cell responses. Journal of Clinical Investigation, 118(3), 1017-1026. [More Information]
  • Mix, H., Weller-Norman, C., Thimme, R., Ahlenstiel, G., Shin, E., Herkel, J., David, C., Lohse, A., Rehermann, B. (2008). Identification of CD4 T-cell epitopes in soluble liver antigen/liver pancreas autoantigen in autoimmune hepatitis. Gastroenterology, 135(6), 2107-2118. [More Information]
  • Caggiari, L., De Zorzi, M., Ahlenstiel, G., Rehermann, B., De Re, V. (2008). Identification of new major histocompatibility complex-A, -B, -C alleles in chimpanzees (Pan troglodytes). Tissue Antigens: immune response genetics, 72(1), 79-83. [More Information]
  • Nattermann, J., Vogel, M., Nischalke, H., Danta, M., Ahlenstiel, G., Michalk, M., Sauerbruch, T., Rockstroh, J., Spengler, U. (2008). The transforming growth factor-beta high-producer genotype is associated with response to hepatitis C virus-specific therapy in HIV-positive patients with acute hepatitis C. AIDS, 22(11), 1287-1292. [More Information]
  • Ahlenstiel, G., Roomp, K., Daumer, M., Nattermann, J., Vogel, M., Rockstroh, J., Beerenwinkel, N., Kaiser, R., Nischalke, H., Sauerbruch, T., et al (2007). Selective pressures of HLA genotypes and antiviral therapy on human immunodeficiency virus type 1 sequence mutation at a population level. Clinical and Vaccine Immunology, 14(10), 1266-1273. [More Information]
  • Ahlenstiel, G., Nischalke, H., Bueren, K., Berg, T., Vogel, M., Biermer, M., Grunhage, F., Sauerbruch, T., Rockstroh, J., Spengler, U., et al (2007). The GNB3 C825T polymorphism affects response to HCV therapy with pegylated interferon in HCV/HIV co-infected but not in HCV mono-infected patients. Journal of Hepatology, 47(3), 384-355. [More Information]
  • Ahlenstiel, G., Feldmann, G., Nattermann, J., Nischalke, H., Gorschluter, M., Kuntzen, T., Gerhardt, T., Wolff, M., Sauerbruch, T., Spengler, U., et al (2006). Detection of human aspartyl (asparaginyl) beta-hydroxylase and homeobox B7 mRNA in brush cytology specimens from patients with bile duct cancer. Endoscopy, 38(6), 604-609. [More Information]
  • Vogel, M., Lichterfeld, M., Kaufmann, D., Mui, S., Altfeld, M., Voigt, E., Ahlenstiel, G., Kupfer, B., Walker, B., Spengler, U., et al (2006). Structured treatment interruptions following immediate initiation of HAART in eight patients with acute HIV-1 seroconversion. European Journal of Medical Research, 11(7), 273-278. [More Information]
  • Nattermann, J., Ahlenstiel, G., Berg, T., Feldmann, G., Nischalke, H., Muller, T., Rockstroh, J., Woitas, R., Sauerbruch, T., Spengler, U. (2006). The tandem-repeat polymorphism of the DC-SIGNR gene in HCV infection. Journal of Viral Hepatitis, 13(1), 42-46. [More Information]
  • Ahlenstiel, G., Rehermann, B. (2005). Hepatitis C Virus and the Threshold of Natural Killer Cell Inhibition. Hepatology, 41(3), 675-677. [More Information]

2014

  • Beard, M., Ffrench, R., Gowans, E., Helbig, K., Eyre, N., Douglas, M., Grebely, J., Ahlenstiel, G., Locarnini, S., George, J., et al (2014). A Summary of the 20(th) International Symposium on Hepatitis C Virus and Related Viruses. Gastroenterology, 147(1), e1-e4. [More Information]
  • Ahlenstiel, G., Hourigan, L., Brown, G., Zanati, S., Williams, S., Singh, R., Moss, A., Sonson, R., Bourke, M. (2014). Actual endoscopic versus predicted surgical mortality for treatment of advanced mucosal neoplasia of the colon. Gastrointestinal Endoscopy, 80(4), 668-676. [More Information]
  • Rotman, Y., Noureddin, M., Feld, J., Guedj, J., Witthaus, M., Han, H., Park, Y., Park, S., Heller, T., Ghany, M., Ahlenstiel, G., et al (2014). Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut (English Edition): an international journal of gastroenterology and hepatology, 63(1), 161-169. [More Information]
  • O'Connor, K., Parnell, G., Patrick, E., Ahlenstiel, G., Suppiah, V., van der Poorten, D., Read, S., Leung, R., Douglas, M., Yang, J., Stewart, G., Liddle, C., George, J., Booth, D. (2014). Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent. Genes and Immunity, 15(2), 88-94. [More Information]
  • Eslam, M., Leung, R., Romero-Gomez, M., Mangia, A., Irving, W., Sheridan, D., Spengler, U., Mollison, L., Cheng, W., Bugianesi, E., Douglas, M., Booth, D., George, J., Ahlenstiel, G., et al (2014). IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. Journal of Hepatology, 61(2), 235-241. [More Information]

2013

  • Suppiah, V., Armstrong, N., O'Connor, K., Berg, T., Weltman, M., Abate, M., Spengler, U., Bassendine, M., Dore, G., Irving, W., Stewart, G., George, J., Booth, D., Ahlenstiel, G., et al (2013). CCR5-Delta32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection. Genes and Immunity, 14(5), 286-290. [More Information]
  • Ahlenstiel, G., Sonson, R., Bourke, M. (2013). Diagnosis and treatment of radiation proctitis. Video Journal and Encyclopedia of GI Endoscopy, 1(2), 316-317. [More Information]
  • Eslam, M., Booth, D., George, J., Ahlenstiel, G. (2013). Interaction of IFNL3 with insulin resistance, steatosis and lipid metabolism in chronic hepatitis C virus infection. World Journal of Gastroenterology, 19(41), 7055-7061. [More Information]
  • O'Day, R., Gillies, M., Ahlenstiel, G. (2013). Ophthalmologic complications of antiviral therapy in hepatitis C treatment. World Journal of Gastroenterology, 19(45), 8227-8237. [More Information]
  • Ahlenstiel, G. (2013). The Natural Killer Cell Response to HCV Infection. Immune Network, 13(5), 168-176. [More Information]

2012

  • Edlich, B., Ahlenstiel, G., Azpiroz, A., Stoltzfus, J., Noureddin, M., Serti, E., Feld, J., Liang, T., Rotman, Y., Rehermann, B. (2012). Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients. Hepatology (Baltimore Md.), 55(1), 39-48. [More Information]
  • Booth, D., Ahlenstiel, G., George, J. (2012). Pharmacogenomics of hepatitis C infections: personalizing therapy. Genome Medicine, 4(12), 1-10. [More Information]
  • Ahlenstiel, G., Booth, D., George, J. (2012). Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms? Antiviral Therapy, 17(6 Pt B), 1163-1170. [More Information]

2011

  • Ahlenstiel, G., Booth, D., George, J. (2011). Clinical significance of IL28B gene variation in hepatitis C virus infection. Hot Topics in viral Hepatitis, (20), 17-24. [More Information]
  • Ahlenstiel, G., Edlich, B., Hogdal, L., Rotman, Y., Noureddin, M., Feld, J., Holz, L., Titerence, R., Liang, T., Rehermann, B. (2011). Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology, 141(4), 1231-1239. [More Information]
  • Smith, K., Suppiah, V., O'Connor, K., Berg, T., Weltman, M., Abate, M., Spengler, U., Bassendine, M., Matthews, G., Irving, W., Ahlenstiel, G., Stewart, G., George, J., Booth, D., et al (2011). Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Medicine, 3(8), 57-1-57-13. [More Information]
  • Suppiah, V., Gaudieri, S., Armstrong, N., O'Connor, K., Berg, T., Weltman, M., Abate, M., Spengler, U., Bassendine, M., Dore, G., Ahlenstiel, G., Stewart, G., George, J., Booth, D., et al (2011). IL28B, HLA-C, and KIR Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort: A Cross-Sectional Study. PLoS Medicine, 8(9), e1001092-1-e1001092-8. [More Information]
  • Feld, J., Modi, A., El-Diwany, R., Rotman, Y., Thomas, E., Ahlenstiel, G., Titerence, R., Koh, C., Cherepanov, V., Heller, T., et al (2011). S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders. Gastroenterology, 140(3), 830-839. [More Information]

2010

  • Ahlenstiel, G., Booth, D., George, J. (2010). IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice. Journal of Gastroenterology and Hepatology, 45(9), 903-910. [More Information]
  • Ahlenstiel, G., Titerence, R., Koh, C., Edlich, B., Feld, J., Rotman, Y., Ghany, M., Hoofnagle, J., Liang, J., Heller, T., et al (2010). Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology, 138, 325-335. [More Information]
  • Vogel, M., Ahlenstiel, G., Hintsche, B., Fenske, S., Trein, A., Lutz, T., Schurmann, D., Stephan, C., Khaykin, P., Bickel, M., et al (2010). The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive Individuals. European Journal of Medical Research, 15(3), 102-111. [More Information]

2009

  • Ahlenstiel, G., Woitas, R., Iwan, A., Nattermann, J., Feldmann, G., Rockstroh, J., Oldenburg, J., Kupfer, B., Sauerbruch, T., Spengler, U. (2009). Effects of the CCR5-Delta32 mutation on hepatitis C virus-specific immune responses in patients with haemophilia. Immunological Investigations, 38(3-4), 284-296. [More Information]
  • Mas Marques, A., Mueller, T., Welke, J., Taube, S., Sarrazin, C., Wiese, M., Halangk, J., Witt, H., Ahlenstiel, G., Spengler, U., et al (2009). Low-density lipoprotein receptor variants are associated with spontaneous and treatment-induced recovery from hepatitis C virus infection. Infection, Genetics and Evolution, 201(5), 27-36. [More Information]
  • Yoon, J., Shjiina, M., Ahlenstiel, G., Rehermann, B. (2009). Natural killer cell function is intact after direct exposure to infectious hepatitis C virions. Hepatology, 49(1), 12-21. [More Information]

2008

  • De Zorzi, M., Caggiari, L., Ahlenstiel, G., Rehermann, B., De Re, V. (2008). Description of two new major histocompatibility complex (MHC) class II DRB1 [Pan troglodytes (Patr)-DRB1] alleles. Tissue Antigens: immune response genetics, 71(5), 490. [More Information]
  • Ahlenstiel, G., Martin, M., Gao, X., Carrington, M., Rehermann, B. (2008). Distinct KIR/HLA compound genotypes affect the kinetics of human antiviral natural killer cell responses. Journal of Clinical Investigation, 118(3), 1017-1026. [More Information]
  • Mix, H., Weller-Norman, C., Thimme, R., Ahlenstiel, G., Shin, E., Herkel, J., David, C., Lohse, A., Rehermann, B. (2008). Identification of CD4 T-cell epitopes in soluble liver antigen/liver pancreas autoantigen in autoimmune hepatitis. Gastroenterology, 135(6), 2107-2118. [More Information]
  • Caggiari, L., De Zorzi, M., Ahlenstiel, G., Rehermann, B., De Re, V. (2008). Identification of new major histocompatibility complex-A, -B, -C alleles in chimpanzees (Pan troglodytes). Tissue Antigens: immune response genetics, 72(1), 79-83. [More Information]
  • Nattermann, J., Vogel, M., Nischalke, H., Danta, M., Ahlenstiel, G., Michalk, M., Sauerbruch, T., Rockstroh, J., Spengler, U. (2008). The transforming growth factor-beta high-producer genotype is associated with response to hepatitis C virus-specific therapy in HIV-positive patients with acute hepatitis C. AIDS, 22(11), 1287-1292. [More Information]

2007

  • Ahlenstiel, G., Rehermann, B. (2007). Hepatic NK, NKT and T Cells. In M Eric Gershwin, John M. Vierling, Michael P. Manns (Eds.), Liver Immunology - Principles and Practice, (pp. 71-82). United States of America: Humana Press, Inc.
  • Ahlenstiel, G., Roomp, K., Daumer, M., Nattermann, J., Vogel, M., Rockstroh, J., Beerenwinkel, N., Kaiser, R., Nischalke, H., Sauerbruch, T., et al (2007). Selective pressures of HLA genotypes and antiviral therapy on human immunodeficiency virus type 1 sequence mutation at a population level. Clinical and Vaccine Immunology, 14(10), 1266-1273. [More Information]
  • Ahlenstiel, G., Nischalke, H., Bueren, K., Berg, T., Vogel, M., Biermer, M., Grunhage, F., Sauerbruch, T., Rockstroh, J., Spengler, U., et al (2007). The GNB3 C825T polymorphism affects response to HCV therapy with pegylated interferon in HCV/HIV co-infected but not in HCV mono-infected patients. Journal of Hepatology, 47(3), 384-355. [More Information]

2006

  • Ahlenstiel, G., Feldmann, G., Nattermann, J., Nischalke, H., Gorschluter, M., Kuntzen, T., Gerhardt, T., Wolff, M., Sauerbruch, T., Spengler, U., et al (2006). Detection of human aspartyl (asparaginyl) beta-hydroxylase and homeobox B7 mRNA in brush cytology specimens from patients with bile duct cancer. Endoscopy, 38(6), 604-609. [More Information]
  • Vogel, M., Lichterfeld, M., Kaufmann, D., Mui, S., Altfeld, M., Voigt, E., Ahlenstiel, G., Kupfer, B., Walker, B., Spengler, U., et al (2006). Structured treatment interruptions following immediate initiation of HAART in eight patients with acute HIV-1 seroconversion. European Journal of Medical Research, 11(7), 273-278. [More Information]
  • Nattermann, J., Ahlenstiel, G., Berg, T., Feldmann, G., Nischalke, H., Muller, T., Rockstroh, J., Woitas, R., Sauerbruch, T., Spengler, U. (2006). The tandem-repeat polymorphism of the DC-SIGNR gene in HCV infection. Journal of Viral Hepatitis, 13(1), 42-46. [More Information]

2005

  • Ahlenstiel, G., Rehermann, B. (2005). Hepatitis C Virus and the Threshold of Natural Killer Cell Inhibition. Hepatology, 41(3), 675-677. [More Information]

To update your profile click here. For support on your academic profile contact .